Search Results - "Ohkawa, Shinichi"

Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study by UENO, Hideki, IOKA, Tatsuya, SHIMAMURA, Tomotaka, SHO, Masayuki, KITANO, Masayuki, CHENG, Ann-Lii, MIZUMOTO, Kazuhiro, CHEN, Jen-Shi, FURUSE, Junji, FUNAKOSHI, Akihiro, HATORI, Takashi, YAMAGUCHI, Taketo, IKEDA, Masafumi, EGAWA, Shinichi, SATO, Atsushi, OHASHI, Yasuo, OKUSAKA, Takuji, TANAKA, Masao, OHKAWA, Shinichi, YANAGIMOTO, Hiroaki, BOKU, Narikazu, FUKUTOMI, Akira, SUGIMORI, Kazuya, BABA, Hideo, YAMAO, Kenji

“…The present phase III study was designed to investigate the noninferiority of S-1 alone and superiority of gemcitabine plus S-1 compared with gemcitabine alone…”
Get full text

Phase II study of FOLFIRINOX for chemotherapy‐naïve Japanese patients with metastatic pancreatic cancer by Okusaka, Takuji, Ikeda, Masafumi, Fukutomi, Akira, Ioka, Tatsuya, Furuse, Junji, Ohkawa, Shinichi, Isayama, Hiroyuki, Boku, Narikazu

“…The FOLFIRINOX combination of chemotherapy drugs had not been fully evaluated for Japanese pancreatic cancer patients. Therefore, we carried out a phase II…”
Get full text

Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial by Kondo, Masaaki, Morimoto, Manabu, Kobayashi, Satoshi, Ohkawa, Shinichi, Hidaka, Hisashi, Nakazawa, Takahide, Aikata, Hiroshi, Hatanaka, Takeshi, Takizawa, Daichi, Matsunaga, Kotaro, Okuse, Chiaki, Suzuki, Michihiro, Taguri, Masataka, Ishibashi, Takako, Numata, Kazushi, Maeda, Shin, Tanaka, Katsuaki

“…The efficacy of hepatic arterial infusion chemotherapy (HAIC) for advanced hepatocellular carcinoma (HCC) remains unclear. We conducted a multi-center…”
Get full text

Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study by Kindler, Hedy L, Dr, Ioka, Tatsuya, MD, Richel, Dirk J, MD, Bennouna, Jaafar, MD, Létourneau, Richard, MD, Okusaka, Takuji, MD, Funakoshi, Akihiro, MD, Furuse, Junji, MD, Park, Young Suk, MD, Ohkawa, Shinichi, MD, Springett, Gregory M, MD, Wasan, Harpreet S, MB, Trask, Peter C, PhD, Bycott, Paul, PhD, Ricart, Alejandro D, MD, Kim, Sinil, MD, Van Cutsem, Eric, MD

“…Summary Background Axitinib is a potent, selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, and 3. A randomised phase 2 trial of…”
Get full text

Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS‐PC Study by Yamaue, Hiroki, Tsunoda, Takuya, Tani, Masaji, Miyazawa, Motoki, Yamao, Kenji, Mizuno, Nobumasa, Okusaka, Takuji, Ueno, Hideki, Boku, Narikazu, Fukutomi, Akira, Ishii, Hiroshi, Ohkawa, Shinichi, Furukawa, Masayuki, Maguchi, Hiroyuki, Ikeda, Masafumi, Togashi, Yosuke, Nishio, Kazuto, Ohashi, Yasuo

“…Gemcitabine is a key drug for the treatment of pancreatic cancer; however, with its limitation in clinical benefits, the development of another potent…”
Get full text

Japanese phase I study of GC33, a humanized antibody against glypican‐3 for advanced hepatocellular carcinoma by Ikeda, Masafumi, Ohkawa, Shinichi, Okusaka, Takuji, Mitsunaga, Shuichi, Kobayashi, Satoshi, Morizane, Chigusa, Suzuki, Ikue, Yamamoto, Shunsuke, Furuse, Junji

“…GC33 is a humanized mAb against human glypican‐3 (GPC3). In the first‐in‐human study carried out in the USA, GC33 was well tolerated and showed preliminary…”
Get full text

Randomized phase III trial of post-operative chemotherapy for patients with stage I/II/III small bowel adenocarcinoma (JCOG1502C, J-BALLAD) by Kitahara, Hideaki, Honma, Yoshitaka, Ueno, Makoto, Kanemitsu, Yukihide, Ohkawa, Shinichi, Mizusawa, Junki, Furuse, Junji, Shimada, Yasuhiro

“…A randomized phase III trial was initiated in May 2017 to confirm the superiority of post-operative therapy with capecitabine and oxaliplatin over observation…”
Get full text

Phase I/II Study: Experience with the Late Onset of Acute Pancreatitis after the Start of Chemotherapy with Gemcitabine Plus nab-Paclitaxel for Metastatic Pancreatic Cancer by Ueno, Makoto, Nagashima, Fumio, Ueno, Hideki, Ikeda, Masafumi, Ohkawa, Shinichi, Mizuno, Nobumasa, Ioka, Tatsuya, Omuro, Yasushi, Nakajima, Takako Eguchi, Furuse, Junji

“…Gemcitabine plus nab-paclitaxel is the current standard chemotherapy for patients with metastatic pancreatic cancer. We conducted a phase I/II study in Japan,…”
Get full text

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial by Kudo, Masatoshi, Hatano, Etsuro, Ohkawa, Shinichi, Fujii, Hirofumi, Masumoto, Akihide, Furuse, Junji, Wada, Yoshiyuki, Ishii, Hiroshi, Obi, Shuntaro, Kaneko, Shuichi, Kawazoe, Seiji, Yokosuka, Osamu, Ikeda, Masafumi, Ukai, Katsuaki, Morita, Sojiro, Tsuji, Akihito, Kudo, Toshihiro, Shimada, Mitsuo, Osaki, Yukio, Tateishi, Ryosuke, Sugiyama, Gen, Abada, Paolo Benjamin, Yang, Ling, Okusaka, Takuji, Zhu, Andrew Xiuxuan

“…Background REACH evaluated ramucirumab in the second-line treatment of patients with advanced hepatocellular carcinoma. In the intent-to-treat population ( n…”
Get full text

Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer by Okusaka, Takuji, Furuse, Junji, Funakoshi, Akihiro, Ioka, Tatsuya, Yamao, Kenji, Ohkawa, Shinichi, Boku, Narikazu, Komatsu, Yoshito, Nakamori, Shoji, Iguchi, Haruo, Ito, Tetsuhide, Nakagawa, Kazuhiko, Nakachi, Kohei

“…Erlotinib combined with gemcitabine has not been evaluated in Japanese patients with unresectable pancreatic cancer. This two‐step phase II study assessed the…”
Get full text

Prediction model for pancreatic cancer risk in the general Japanese population by Nakatochi, Masahiro, Lin, Yingsong, Ito, Hidemi, Hara, Kazuo, Kinoshita, Fumie, Kobayashi, Yumiko, Ishii, Hiroshi, Ozaka, Masato, Sasaki, Takashi, Sasahira, Naoki, Morimoto, Manabu, Kobayashi, Satoshi, Ueno, Makoto, Ohkawa, Shinichi, Egawa, Naoto, Kuruma, Sawako, Mori, Mitsuru, Nakao, Haruhisa, Wang, Chaochen, Nishiyama, Takeshi, Kawaguchi, Takahisa, Takahashi, Meiko, Matsuda, Fumihiko, Kikuchi, Shogo, Matsuo, Keitaro

“…Genome-wide association studies (GWASs) have identified many single nucleotide polymorphisms (SNPs) that are significantly associated with pancreatic cancer…”
Get full text

Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib by Morimoto, Manabu, Numata, Kazushi, Kondo, Masaaki, Hidaka, Hisashi, Takada, Juichi, Shibuya, Akitaka, Kobayashi, Satoshi, Ohkawa, Shinichi, Okuse, Chiaki, Morita, Satoshi, Taguri, Masataka, Tanaka, Katsuaki

“…Aim:  Sorafenib is approved for the treatment of advanced hepatocellular carcinoma (HCC) in Japan; however, its tolerability and efficacy in elderly patients…”
Get full text

Field practice study of half-dose sorafenib treatment on safety and efficacy for hepatocellular carcinoma: A propensity score analysis by Morimoto, Manabu, Numata, Kazushi, Kondo, Masaaki, Kobayashi, Satoshi, Ohkawa, Shinichi, Hidaka, Hisashi, Nakazawa, Takahide, Okuwaki, Yusuke, Okuse, Chiaki, Matsunaga, Kotaro, Suzuki, Michihiro, Morita, Satoshi, Taguri, Masataka, Tanaka, Katsuaki

“…Aim Patients with hepatocellular carcinoma (HCC) who receive an initial full dose of sorafenib (800 mg/day) often require a decreased dose (400 mg/day) or…”
Get full text

Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial by Ioka, Tatsuya, Okusaka, Takuji, Ohkawa, Shinichi, Boku, Narikazu, Sawaki, Akira, Fujii, Yosuke, Kamei, Yoichi, Takahashi, Satori, Namazu, Katsushi, Umeyama, Yoshiko, Bycott, Paul, Furuse, Junji

“…Axitinib is a potent and selective inhibitor of vascular endothelial growth factor receptors 1-3. This analysis compared efficacy and safety of axitinib plus…”
Get full text

Metastatic Pancreatic Neuroendocrine Tumor that Progressed to Ectopic Adrenocorticotropic Hormone (ACTH) Syndrome with Growth Hormone-releasing Hormone (GHRH) Production by Tadokoro, Rie, Sato, Shotaro, Otsuka, Fumiko, Ueno, Makoto, Ohkawa, Shinichi, Katakami, Hideki, Taniyama, Matsuo, Nagasaka, Shoichiro

“…The patient was a 61-year-old woman who had a well-differentiated pancreatic neuroendocrine tumor (PNET) with lymph node metastasis. After 15 months of…”
Get full text

Genome-wide association study-identified SNPs (rs3790844, rs3790843) in the NR5A2 gene and risk of pancreatic cancer in Japanese by Ueno, Makoto, Ohkawa, Shinichi, Morimoto, Manabu, Ishii, Hiroshi, Matsuyama, Masato, Kuruma, Sawako, Egawa, Naoto, Nakao, Haruhisa, Mori, Mitsuru, Matsuo, Keitaro, Hosono, Satoyo, Nojima, Masanori, Wakai, Kenji, Nakamura, Kozue, Tamakoshi, Akiko, Takahashi, Mami, Shimada, Kazuaki, Nishiyama, Takeshi, Kikuchi, Shogo, Lin, Yingsong

“…We genotyped 2 SNPs (rs3790844 T/C and rs3790843 G/A) in the NR5A2 gene that were identified in a genome-wide association study (GWAS) of pancreatic cancer in…”
Get full text

The clinico-pathological character of pancreatic adenosquamous carcinoma by Ohkawa, Shinichi, Ohike, Nobuyuki

Get more information

Switch to miriplatin for multinodular hepatocellular carcinoma unresponsive to transarterial chemoembolization with epirubicin: a prospective study by Goda, Yoshihiro, Morimoto, Manabu, Irie, Kuniyasu, Kobayashi, Satoshi, Ueno, Makoto, Moriya, Satoshi, Tezuka, Shun, Ohkawa, Shinichi, Morinaga, Soichiro, Numata, Kazushi, Tanaka, Katsuaki, Maeda, Shin

“…The aim of this prospective study was to evaluate the efficacy of transarterial chemoembolization using miriplatin, a platinum-based anticancer drug, as a…”
Get full text

Response to Y. Sasaki et al.: Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer? by Okusaka, Takuji, Ikeda, Masafumi, Fukutomi, Akira, Ioka, Tatsuya, Furuse, Junji, Ohkawa, Shinichi, Isayama, Hiroyuki, Boku, Narikazu

“…[...]to introduce the FOLFIRINOX therapy as early as possible in Japan, we used the same dosing regimen as that in the ACCORD11 study. When we planned this…”
Get full text

Phase II Study of Gemcitabine Chemotherapy Alone for Locally Advanced Pancreatic Carcinoma: JCOG0506 by Ishii, Hiroshi, Furuse, Junji, Boku, Narikazu, Okusaka, Takuji, Ikeda, Masafumi, Ohkawa, Shinichi, Fukutomi, Akira, Hamamoto, Yasuo, Nakamura, Kenichi, Fukuda, Haruhiko

“…Objective Chemoradiotherapy with 5-fluorouracil has been accepted as a standard care for locally advanced pancreatic cancer; however, it has not been shown to…”
Get full text